Clinical Trial Update: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib malate in patients with recurrent or metastatic endometrial cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Cancer
• Endometrial Endometrioid Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Stage Iva Uterine Corpus Cancer
• Stage Ivb Uterine Corpus Cancer
• Uterine Carcinosarcoma
• Uterine Corpus Carcinoma
• Uterine Corpus Carcinosarcoma

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-17